Global Diabetes Devices Market Growth, Trends & Forecasts 2017 - 2022

  • ID: 4387218
  • Report
  • Region: Global
  • 206 pages
  • Mordor Intelligence
1 of 4
The global diabetes market is estimated at USD 10.65 billion market in 2014 and is forecasted to reach USD 15.37 billion by 2019 with a CAGR of about 7%. Diabetes is a chronic metabolic disease characterized by high blood sugar, wherein the body is either not able to produce insulin (type-1) or is not able to utilize the generated insulin (type-2). According to Centers for Disease Control and Prevention (CDC), diabetes is the seventh leading cause of death in the United States.

Patients with diabetes will typically experience frequent urination (polyuria), increased thirst (polydipsia) and increased hunger (polyphagia). If diabetes is not controlled, it can lead to serious health complications including heart diseases, kidney diseases, stroke, amputations of the legs and feet, blindness and early death.

The diabetes market is majorly driven by the rise in the number of people with diabetes, complexities in alternative diabetes therapy and strong encouragement from the Governments. However, the lack of proper regulatory framework, lack of public awareness of the disease and cost sensitivity issues are hindering the growth of the market.

The diabetes market can be segmented into diabetes care devices: glucose monitoring devices and insulin delivery devices; and therapy type: injectable and oral drugs. Glucose monitoring devices has been further segmented into blood glucose meters, blood glucose test strips, lancing devices, continuous glucose monitoring devices. Insulin delivery devices are also sub segmented into insulin pump, insulin syringe and insulin pen.

The diabetes market can be geographically segmented into Asia Pacific, Europe, North America, and Rest of the World, with North America dominating the global market currently. Asia Pacific is also an emerging market which has a scope for growth and can potentially dominate the market in the future.

Key Deliverables:

Market analysis for the global diabetes market, with region specific assessments and competition analysis on global and regional scales.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market shares.

Identification and analysis of the macro and micro factors that affect the global diabetes market on both global and regional scales.

A comprehensive list of key market players along with the analysis of their current strategic interests.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. INTRODUCTION
1.1 Report Description
1.2 Research Methodology
1.3 Stakeholders
2. EXECUTIVE SUMMARY
2.1 Key Findings
2.2 Market Overview
3. MARKET OVERVIEW
3.1 Market Definition
3.1.1 Introduction
3.2 Market Segmentation
3.2.1 Diabetes Care Devices
3.2.1.1 Glucose Monitoring Devices
3.2.1.1.1 Blood Glucose Meters
3.2.1.1.2 Blood Glucose Test Strips
3.2.1.1.3 Lancing Devices
3.2.1.1.4 Continuous Glucose Monitoring Devices
3.2.1.2 Insulin Delivery Devices
3.2.1.2.1 Insulin Pumps
3.2.1.2.3 Insulin Syringes
3.2.1.2.4 Insulin Pens
3.2.2 Therapy Type
3.2.2.1 Injectable
3.2.2.2 Oral Drugs
3.2.3 Geography
3.2.3.1 Asia Pacific
3.2.3.2 Europe
3.2.3.3 North America
3.2.3.4 Rest of the World
3.3 Market Drivers
3.3.1 Rise in number of people with diabetes
3.3.2 Complexities in alternative diabetes therapy
3.3.3 Government Initiatives
3.4 Market Challenges
3.4.1 Regulatory Framework
3.4.2 Low awareness
3.4.3 Cost sensitivity
4. NORTH AMERICA MARKETS: SEGMENTATION BY DRUGS
4.1 Insulin Derivatives
4.1.1 Rapid acting insulin
4.1.2 Intermediate acting insulin
4.1.3 Long acting insulin
4.2 Oral Diabetic Medication Drugs
4.2.1 Sulfonyulrea
4.2.2 Metformin
4.2.3 Alpha-Glucosidace inhibitor
4.2.4 Thiazolidinediones
4.2.5 Biguanide
4.2.6 Meglitinides
4.2.7 GPP4-Inhibitors
5. NORTH AMERICAN MARKETS: SEGMENTATION BY GEOGRAPHY
5.1 USA
5.2 Canada
5.3 Mexico
6. COMPETITIVE LANDSCAPE
6.1 Introduction
6.2 Mergers & Acquisitions
6.3 Expansions
6.4 New Product Launch
6.5 Collaborations
7. COMPANY PROFILES
7.1 Abbott Laboratories
7.2 Dexcom Inc.
7.3 Johnson & Johnson
7.4 Merck & Co.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll